Market Place
Sourcing Support
Hemogenyx Pharmaceuticals Announces Annual General Meeting Notice
05 Jun 2026 //
ACCESSWIRE
Hemogenyx Pharma Grants Options, Extends Warrant Terms
29 May 2026 //
PHARMIWEB
Hemogenyx Pharmaceuticals PLC Announces Final Results
30 Apr 2026 //
PHARMIWEB
Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise
28 Apr 2026 //
PHARMIWEB
Hemogenyx Pharma Reports Annual IND To FDA
14 Apr 2026 //
PHARMIWEB
Hemogenyx Completes Tech Transfer and Updates on Clinical Trial
31 Mar 2026 //
PHARMIWEB
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
27 Feb 2026 //
PHARMIWEB
Hemogenyx Pharma Executes Warrants, Releases Equity
23 Feb 2026 //
PHARMIWEB
Hemogenyx Pharma Updates Share Admission
22 Dec 2025 //
PHARMIWEB
Hemogenyx Pharma PLC Issues Equity
18 Dec 2025 //
PHARMIWEB
Hemogenyx Pharmaceuticals PLC Announces Publication Of Prospectus
19 Nov 2025 //
PHARMIWEB
Hemogenyx Pharma Updates Clinical Trial, Grants Share Awards
29 Oct 2025 //
ACCESSWIRE
Hemogenyx Pharma Cleared To Start Enrolling Pediatric Patients
06 Oct 2025 //
PHARMAWEB
Hemogenyx Pharmaceuticals Plc Announces Half-Year Report
30 Sep 2025 //
ACCESSWIRE
Hemogenyx Pharma PLC Signs Letter of Intent
23 Sep 2025 //
ACCESSWIRE
Hemogenyx Pharma PLC Announces Third Patient Safety
17 Sep 2025 //
PHARMAWEB
Hemogenyx Pharma Invited to DCNY Summit
11 Sep 2025 //
ACCESSWIRE
Hemogenyx Pharma Partners with Made Scientific for Manufacturing
09 Sep 2025 //
PHARMIWEB
Hemogenyx Pharmaceuticals PLC Issues Convertible Loan Notes
01 Sep 2025 //
PHARMAWEB
Hemogenyx Pharmaceuticals PLC Announces Result of Audit Tender
29 Aug 2025 //
PHARMAWEB
Hemogenyx raises £570,000 and Director`s Dealing
26 Aug 2025 //
PHARMAWEB
Hemogenyx treats third patient with HG-CT-1 CAR-T therapy
15 Aug 2025 //
PHARMAWEB
Hemogenyx Pharma Raises £250,000, Announces Director`s Deal
29 Jul 2025 //
ACCESSWIRE
Hemogenyx Receives Grant
16 Jul 2025 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Raises £451,250 in Placing
03 Jun 2025 //
ACCESSWIRE
Hemogenyx Pharma Announces Placing to Raise £451,250
08 May 2025 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Recruits Second Patient for Trials
17 Mar 2025 //
ACCESSWIRE
Hemogenyx Pharmaceuticals Announces Institutional Investment
11 Mar 2025 //
ACCESSWIRE
Hemogenyx Pharma Announces First-in-Human Treatment with HG-CT-1
24 Feb 2025 //
ACCESSWIRE
Hemogenyx Pharma PLC Announces Issue of Convertible Loan Notes
19 Feb 2025 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000
08 Jan 2025 //
ACCESSWIRE
Hemogenyx Pharmaceuticals Opens First Clinical Site
30 Dec 2024 //
ACCESSWIRE
Hemogenyx Announces Ultrafast CAR-T Manufacturing
19 Dec 2024 //
ACCESSWIRE
Hemogenyx Pharma Announces Admission of New Ordinary Shares
10 Dec 2024 //
ACCESSWIRE
Hemogenyx Pharma PLC Announces Site Initiation Visit Completed
09 Dec 2024 //
ACCESSWIRE
Hemogenyx Pharma PLC Announces CBR Macrophage Delivery Update
05 Dec 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase I Trial
22 Nov 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals Announces Extraordinary General Meeting
22 Nov 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
11 Nov 2024 //
ACCESSWIRE
Hemogenyx Receives Investment From Prevail Partners
02 Oct 2024 //
ACCESSWIRE
Hemogenyx`s FLT3 Assay Ready For Phase I At MD Anderson
08 Sep 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
02 Sep 2024 //
ACCESSWIRE
Hemogenyx To Present At Macrophage-Directed Therapies Summit
29 Jul 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Posting of Annual Report & Notice of AGM
03 Jun 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
14 Feb 2024 //
ACCESSWIRE
Hemogenyx Announces Submission of Complete Response to Clinical Hold
16 Jan 2024 //
ACCESSWIRE
Hemogenyx Announces HEMO-CAR-T Process Qualification Run Completed
08 Jan 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
27 Nov 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-Year Report
28 Sep 2023 //
ACCESSWIRE
Hemogenyx Pharma Announces Strategic Investment from Prevail Partners, LLC
18 Sep 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Patent Application Update
08 Sep 2023 //
ACCESSWIRE
Hemogenyx gets clarity on cause of FDA clinical hold on CAR-T
11 Jul 2023 //
FIERCE BIOTECH
Hemogenyx Pharmaceuticals PLC Announces Full FDA Review for HEMO-CAR-T IND
10 Jul 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Submission of IND for HEMO-CAR-T
09 May 2023 //
ACCESSWIRE
Hemogenyx Announces Final Results for the Year Ended 31 December 2022
28 Apr 2023 //
ACCESSWIRE
Hemogenyx Announces Equity Incentive Pool Increase and Option Grant
28 Apr 2023 //
ACCESSWIRE
Hemogenyx Pharma PLC Announces HEMO-CAR-T Analytical Release Tests Completed
23 Mar 2023 //
ACCESSWIRE
Hemogenyx PLC Announces HEMO-CAR-T Process Qualification Run Completed
04 Jan 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - HEMO-CAR-T First PQ Run Completed
12 Dec 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
29 Sep 2022 //
ACCESSWIRE
